The iconic rise of Viagra has long been a symbol of pharmaceutical success, yet its future within the broader industry now presents questions about long-term returns . Alternative versions are undercutting patent protection , prompting anxieties that investing in companies heavily reliant to Viagra's former position could be a problematic strategy,